➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Medtronic
Express Scripts
Boehringer Ingelheim
Merck
Colorcon
Dow

Last Updated: July 10, 2020

DrugPatentWatch Database Preview

RESERPINE Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

When do Reserpine patents expire, and when can generic versions of Reserpine launch?

Reserpine is a drug marketed by Barr, Bell Pharma, Bundy, Cycle Pharms Ltd, Elkins Sinn, Everylife, Halsey, Hikma Intl Pharms, Impax Labs, Ivax Sub Teva Pharms, Marshall Pharma, Mk Labs, Mylan, Pharmavite, Purepac Pharm, Pvt Form, Rexall, Sandoz, Solvay, Tablicaps, Teva, Valeant Pharm Intl, Watson Labs, Whiteworth Town Plsn, West Ward, Ivax Pharms, Par Pharm, Sun Pharm Industries, and Lederle. and is included in forty-one NDAs.

The generic ingredient in RESERPINE is hydralazine hydrochloride; hydrochlorothiazide; reserpine. There are twenty-one drug master file entries for this compound. Additional details are available on the hydralazine hydrochloride; hydrochlorothiazide; reserpine profile page.

Summary for RESERPINE
Drug patent expirations by year for RESERPINE
Recent Clinical Trials for RESERPINE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Mansoura UniversityPhase 4
Mayo ClinicPhase 1
University of Alabama at BirminghamPhase 2

See all RESERPINE clinical trials

Medical Subject Heading (MeSH) Categories for RESERPINE

US Patents and Regulatory Information for RESERPINE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva RESERPINE reserpine TABLET;ORAL 089020-001 Mar 7, 1985 DISCN No No   Start Trial   Start Trial   Start Trial
Pvt Form RESERPINE reserpine TABLET;ORAL 086117-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
Whiteworth Town Plsn RESERPINE reserpine TABLET;ORAL 080723-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
Watson Labs RESERPINE, HYDRALAZINE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE hydralazine hydrochloride; hydrochlorothiazide; reserpine TABLET;ORAL 085549-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
Watson Labs RESERPINE reserpine TABLET;ORAL 080679-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
Whiteworth Town Plsn RESERPINE reserpine TABLET;ORAL 080723-002 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Express Scripts
Boehringer Ingelheim
Merck
Colorcon
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.